Crinetics Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
Good afternoon, everyone. My name is Jess Fye. I'm a biotech analyst at JPMorgan, and we are delighted to be continuing the conference today with Crinetics.
We're going to have a Q&A session in this room after the presentation. (Operator Instructions) So with that, let me turn it over to Crinetics' CEO, Scott Struthers for the presentation.
Thank you, Jess. Thank you, everybody, for coming. It's really good to see people in 3D, although I miss seeing your kids and your dogs and some of the fun things we've had over the pandemic, but this is better.
So I'd like to tell you about Crinetics today. We're building a deep endocrine franchise and a company that can support it, time and again from product to product from discovery and soon into commercialization, being led by our Phase III program, which will read out this year, but there's a lot more behind that. So I'm going to
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |